Clinical trial
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With…
NCT00052598 · Fred Hutchinson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00052598 |
|---|---|
| Title | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant |
| Official title | Phase I/II Study of Adoptive Immunotherapy With CD8+ Proteinase 3 (Myeloblastin)-Specific CTL Clones for HLA-A2+ Patients With Relapse or Progression of Disease After Allogeneic Hematopoietic Stem Cell Transplant for High Risk Myeloid Leukemias |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16 and 10 more |
| Intervention type | Biological, Other |
| Interventions | therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, flow cytometry |
| Enrollment | 7 |
| Start date | Sep 1, 2002 |
| Primary completion | Nov 1, 2009 |
| Completion | Jun 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: